checkAd

     185  0 Kommentare Mosaic ImmunoEngineering Announces Issuance of U.S. Patent Covering Cancer Treatment with Its Lead Immuno-Oncology Candidate MIE-101 - Seite 3

    Contact:
    Jay Carlson
    Sr. Manager, Investor Relations
    Mosaic ImmunoEngineering, Inc.
    info@mosaicie.com

    Strategic corporate inquiries can be sent to partnering@mosaicie.com

    Lesen Sie auch

    SOURCE: Mosaic ImmunoEngineering Inc.



    View source version on accesswire.com:
    https://www.accesswire.com/748458/Mosaic-ImmunoEngineering-Announces-I ...


    The Mosaic ImmunoEngineering Stock at the time of publication of the news with a fall of -5,88 % to 0,800USD on Nasdaq OTC stock exchange (10. April 2023, 23:20 Uhr).

    Accesswire
    0 Follower
    Autor folgen
    Mehr anzeigen
    We’re a newswire service standout and fast becoming an industry disruptor. We provide regional, national and global news to thousands of clients around the world. We’re also leading the way in social engagement, targeting and analytics.
    Mehr anzeigen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von Accesswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Mosaic ImmunoEngineering Announces Issuance of U.S. Patent Covering Cancer Treatment with Its Lead Immuno-Oncology Candidate MIE-101 - Seite 3 - Issued patents include important claims covering methods of treating cancer using MIE-101 as a single agent or in combination with other treatment modalities -- MIE-101 has demonstrated potent, durable, and systemic antitumor activity in multiple …